文献速递类风湿关节炎

托法替布与恶性肿瘤风险:类风湿关节炎常规诊疗患者中托法替布安全性(STAR-RA)研究结果

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
PubMed 文献 · Arthritis Rheumatol · 2022-09-01

基于美国保险索赔数据构建类风湿关节炎患者队列,比较托法替布与肿瘤坏死因子抑制剂(TNFi)的恶性肿瘤风险。真实世界证据队列中合并加权HR为1.01(95%CI 0.83, 1.22),未发现托法替布较TNFi增加恶性肿瘤风险的证据,但不能排除更长疗程下风险增加的可能。

要点

  • 真实世界证据队列中,托法替布较TNFi的任意恶性肿瘤合并加权HR为1.01(95%CI 0.83, 1.22)。
  • 模拟ORAL Surveillance入排标准的RCT重复队列中,HR为1.17(95%CI 0.85, 1.62)。
  • ORAL Surveillance试验报告的HR为1.48(95%CI 1.04, 2.09),本研究结果不能排除更长疗程下风险增加的可能。

核心结论

  • 在真实世界诊疗的类风湿关节炎患者中,未发现托法替布治疗较TNFi治疗增加恶性肿瘤发生风险的证据。
  • 但研究结果不能排除随托法替布治疗时间延长而风险增加的可能性。

研究设计与样本

  • 使用Optum Clinformatics(2012-2020)、IBM MarketScan Research Databases(2012-2018)和Medicare(A、B、D部分,2012-2017)的美国保险索赔数据。
  • 构建两个类风湿关节炎患者队列:真实世界证据(RWE)队列来自常规诊疗,RCT重复队列模拟ORAL Surveillance试验的入排标准。
  • 采用倾向评分精细分层加权的Cox比例风险模型估计风险比(HR)及95%置信区间(95%CI)。
  • 各数据库估计值采用逆方差加权固定效应模型进行Meta分析。

主要发现

  • RWE队列共83,295例患者,其中10,504例(12.6%)接受托法替布治疗。
  • RWE队列中,托法替布较TNFi的任意恶性肿瘤(排除非黑色素瘤皮肤癌)合并加权HR为1.01(95%CI 0.83, 1.22)。
  • RCT重复队列中,托法替布较TNFi的任意恶性肿瘤合并加权HR为1.17(95%CI 0.85, 1.62)。
  • ORAL Surveillance试验报告的HR为1.48(95%CI 1.04, 2.09)。

关键数值与推荐

  • 主要结局为任意恶性肿瘤(排除非黑色素瘤皮肤癌)。
  • RWE队列中托法替布较TNFi的合并加权HR为1.01(95%CI 0.83, 1.22)。
  • RCT重复队列中托法替布较TNFi的合并加权HR为1.17(95%CI 0.85, 1.62)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究结果不能排除随托法替布治疗时间延长而风险增加的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Results of the ORAL Surveillance safety trial have indicated that there is an increased risk for the development of malignancies with tofacitinib therapy when compared to treatment with tumor necrosis factor inhibitors (TNFi). This study was undertaken to further examine this safety concern in rheumatoid arthritis (RA) patients in a real-world setting. METHODS: Using US insurance claims data from Optum Clinformatics (2012-2020), IBM MarketScan Research Databases (2012-2018), and Medicare (parts A, B, and D, 2012-2017), we created 2 cohorts of RA patients who had initiated treatment with tofacitinib or TNFi. The first cohort, designated the real-world evidence (RWE) cohort, included RA patients from routine care. For the second cohort, designated the randomized controlled trial (RCT)-duplicate cohort, we emulated the inclusion and exclusion criteria that were applied in the ORAL Surveillance trial of tofacitinib, which allowed us to assess the comparability of our results with the results of that trial. Cox proportional hazards models with propensity score fine-stratification weighting were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the risk of any malignancy (excluding nonmelanoma skin cancer). Database-specific estimates were meta-analyzed using fixed-effects models with inverse-variance weighting. RESULTS: The RWE cohort consisted of 83,295 patients, including 10,504 patients (12.6%) who received treatment with tofacitinib. The pooled weighted HR for the primary outcome of any malignancy associated with tofacitinib treatment compared to any malignancy associated with TNFi therapy was 1.01 (95% CI 0.83, 1.22) in the RWE cohort and 1.17 (95% CI 0.85, 1.62) in the RCT-duplicate cohort (compared to the ORAL Surveillance trial HR of 1.48 [95% CI 1.04, 2.09]). CONCLUSION: We did not find evidence of an increased risk of malignancy development with tofacitinib therapy, in comparison with TNFi therapy, in RA patients treated in a real-world setting. However, our results cannot rule out the possibility of an increase in risk that may accrue with a longer duration of treatment with tofacitinib.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Khosrow-Khavar F, Desai RJ, Lee H, et al. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol. 2022. PMID: 35643956. doi:10.1002/art.42250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。